<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00326989</url>
  </required_header>
  <id_info>
    <org_study_id>2005-005709-50</org_study_id>
    <secondary_id>Cellwave CHF</secondary_id>
    <nct_id>NCT00326989</nct_id>
  </id_info>
  <brief_title>Cell-Wave Study: Combined Extracorporal Shock Wave Therapy and Intracoronary Cell Therapy in Chronic Ischemic Myocardium</brief_title>
  <official_title>Extracorporal Shock Wave Therapy for Induction of Therapeutic Neovascularization and Homing of Bone Marrow Progenitor Cells in Patients With Chronic Ischemic Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Extracorporal shock wave therapy is performed prior to cell therapy for induction of
      therapeutic neovascularization and improvement of homing of bone marrow progenitor cells in
      patients with chronic ischemic heart disease following anterior myocardial infarction.

      Shock waves can induce growth factor expression in the ischemic myocardium and might augment
      homing of autologous bone marrow mononuclear cells which are injected intracoronary 24 h
      following shock wave therapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single center, Phase I-II Study (Safety, Feasibility and Efficacy) Double-blind, randomised
      trial (Cell therapy), single blind (Shockwave)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in global ejection fraction on LV angiography</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global or regional wall motion at 4 months and 1 year</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA Class</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT BNP levels</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life quality</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>Low-dose shock wave treatment &amp; Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>low-dose shock-wave treatment &amp; Cell therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose shock-wave treatment &amp; Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose shock-wave treatment &amp; cell therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo shock-wave treatment &amp; cell therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>intracoronary stem cell therapy</intervention_name>
    <description>extracorporal shock waves prior to intracoronary cell therapy</description>
    <arm_group_label>Low-dose shock wave treatment &amp; Placebo</arm_group_label>
    <arm_group_label>low-dose shock-wave treatment &amp; Cell therapy</arm_group_label>
    <arm_group_label>High-dose shock-wave treatment &amp; Placebo</arm_group_label>
    <arm_group_label>High-dose shock-wave treatment &amp; cell therapy</arm_group_label>
    <arm_group_label>Placebo shock-wave treatment &amp; cell therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with chronic ischemic heart disease

          -  Patients with anterior myocardial infarction &gt; 3months

          -  EF &lt; 50% or NYHA II-IV

          -  Age 18-80

          -  Informed consent

        Exclusion Criteria:

          -  Ventricular thrombus

          -  Infarct &lt; 3 months.

          -  Active infection or fever

          -  Chronic inflammatory disease (e.g M. Crohn, Rheumatoid Arthritis)

          -  HIV Infection oder active Hepatitis

          -  Neoplastic disease w/o complete remission within 5 years

          -  Stroke &lt; 3months

          -  Creatinine &gt; 2 mg/dl

          -  Relevant Liver disease (GOT &gt; twice the upper limit).

          -  Anemia (Hemoglobin &lt;10 mg/dl)

          -  Thrombocytopenia &lt; 100.000/Âµl

          -  Allergies to Aspirin, Clopidogrel, Heparin

          -  History of bleeding disorder

          -  History of coagulopathy

          -  Gastrointestinal Bleeding &lt; 3 months

          -  Surgery or Trauma &lt; 2 months

          -  Pregnancy

          -  Mental Retardation

          -  Participation in other clinical study &lt; 1 month
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas M Zeiher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Div. of Cardiology, University of Frankfurt, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dirk H Walter, MD</last_name>
    <role>Study Director</role>
    <affiliation>Div. of Cardiology, University of Frankfurt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Div. of Cardiology , University of Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2006</study_first_submitted>
  <study_first_submitted_qc>May 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2006</study_first_posted>
  <last_update_submitted>March 20, 2017</last_update_submitted>
  <last_update_submitted_qc>March 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospital</investigator_affiliation>
    <investigator_full_name>A. M. Zeiher</investigator_full_name>
    <investigator_title>Prof. Dr. Andreas M. Zeiher</investigator_title>
  </responsible_party>
  <keyword>Extracorporal shock wave therapy</keyword>
  <keyword>Cell therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

